Inclusion Criteria:

- Adult patients >/= 21 years of age

- Advanced or metastatic and/or unresectable hepatocellular carcinoma

- At least 1 measurable lesion according to RECIST criteria

- Primary tumor in situ (Expansion Cohort Part I, Part II)

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Adequate bone marrow, liver and renal function

Exclusion Criteria:

- Prior systemic treatment for metastatic hepatocellular carcinoma or patients who had
tumor removed (Expansion Cohort Part I, Part II)

- Major surgery within previous 4 weeks or planned major surgical procedure during
course of study

- Radiation therapy within 28 days prior to start of study treatment

- Serious non-healing wound, ulcer ore bone fracture

- History of uncontrolled seizures or encephalopathy within the last 6 months

- Current central nervous system (CNS) metastases or spinal cord compression

- History of gastrointestinal perforation or esophageal/gastric bleeding within 6
months prior to study enrollment

- History of another primary malignancy and off treatment for non-melanoma skin cancer and carcinoma in situ of the cervix

- Patients with prior liver transplant

- Inadequately controlled hypertension or prior history of hypertensive crisis or
hypertensive encephalopathy

- Active bleeding diathesis